EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Prognostic Stratification of Adjuvant Immunotherapy After Neoadjuvant Chemoimmunotherapy and Quality Surgery in LA-ESCC

Jingwei Sun, Peilong Bao, Yuquan Bai, Chunji Chen, Huilai Lv, Jiangbo Lin, Changchun Wang, Jianfei Shen, Xinyu Mei, Yongtao Han, Zhichao Liu, Zhenyang Zhang und 15 weitere

The Journal of Thoracic and Cardiovascular Surgery · 2026-10

DOI: 10.1016/j.jtcvs.2026.10.010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Thoracic and Cardiovascular Surgery, 2026-10. Verfasst von Jingwei Sun und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Tangdu Hospital, The Fourth Military Medical University, Xi'an, China. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: In locally advanced esophageal squamous cell carcinoma (LA-ESCC), neoadjuvant chemoimmunotherapy (NCIT) plus high-quality surgery (R0 resection with systematic lymphadenectomy >19 nodes) is a promising strategy. However, the value of adjuvant immunotherapy remains unclear. This study aimed to evaluate the association between postoperative adjuvant immunotherapy and survival outcomes in a multicenter cohort. METHODS: This multicenter retrospective study enrolled LA-ESCC patients receiving NCIT from eight high-volume Chinese centers between 2019 and 2023. After screening for high-quality surgery, propensity score matching (PSM) balanced characteristics between the two groups: NCIT plus surgery (NCIT+S) and NCIT plus surgery followed by adjuvant immunotherapy (NCIT+S+ICI). The primary endpoints were overall survival (OS) and disease-free survival (DFS). A prognostic framework based on major pathological response (MPR) and postoperative pathological N stage (ypN) was constructed to refine patient selection. RESULTS: Among 724 patients with a median follow-up of 40.3 months, 3-year OS and DFS rates were 73.0% and 67.7%, respectively. After PSM, adjuvant immunotherapy significantly improved DFS (77.1% vs 65.8%, log-rank P=0.037), but not OS (83.4% vs 69.4%, log-rank P=0.058). Multivariate analysis identified ypN, MPR, and postoperative adjuvant immunotherapy as independent prognostic factors for DFS. Stratification by MPR and ypN status showed that DFS benefit from adjuvant immunotherapy was restricted to the non-MPR/ypN+ subgroup (HR=0.339; 95% CI: 0.173-0.662; log-rank P

Schlagwörter

Stichwörter der Autor:innen

adjuvant immunotherapyesophageal squamous cell carcinomaimmune checkpoint inhibitorsneoadjuvant chemoimmunotherapy

Autor:innen und Institutionen

  • Department of Thoracic Surgery, Tangdu Hospital, The Fourth Military Medical University, Xi'an, China.
  • Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
  • Clinical Research Center for Thoracic Tumors of Fujian Province, Fuzhou, China; Department of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou, China; Key Laboratory of Cardio-Thoracic Surgery (Fujian…
  • Department of Thoracic Surgery, Zhejiang Cancer Hospital, Hangzhou, China.
  • Department of Thoracic Surgery, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, China; Key Laboratory of Minimally Invasive Techniques & Rapid Rehabilitation of Digestive System T…

Zitieren

APA

Sun, J., Bao, P., Bai, Y., Chen, C., Lv, H., Lin, J., Wang, C., Shen, J., Mei, X., Han, Y., Liu, Z., Zhang, Z., Zhong, Q., Jiang, Y., Xu, L., Li, X., Qian, D., Ma, D., Ye, M., …, & Zhao, J. (2026). Prognostic Stratification of Adjuvant Immunotherapy After Neoadjuvant Chemoimmunotherapy and Quality Surgery in LA-ESCC. The Journal of Thoracic and Cardiovascular Surgery. https://doi.org/10.1016/j.jtcvs.2026.10.010

Vancouver

Sun J, Bao P, Bai Y, Chen C, Lv H, Lin J, et al. Prognostic Stratification of Adjuvant Immunotherapy After Neoadjuvant Chemoimmunotherapy and Quality Surgery in LA-ESCC. The Journal of Thoracic and Cardiovascular Surgery. 2026. doi:10.1016/j.jtcvs.2026.10.010

BibTeX
@article{Sun2026,
  author = {Sun, Jingwei and Bao, Peilong and Bai, Yuquan and Chen, Chunji and Lv, Huilai and Lin, Jiangbo and Wang, Changchun and Shen, Jianfei and Mei, Xinyu and Han, Yongtao and Liu, Zhichao and Zhang, Zhenyang and Zhong, Qihong and Jiang, Youhua and Xu, Liwei and Li, Xiaoyang and Qian, Dong and Ma, Dehua and Ye, Minhua and Wang, Chunguo and Wang, Zimin and Tian, Ziqiang and Leng, Xuefeng and Li, Zhigang and Guo, Xufeng and Yan, Xiaolong and Zhao, Jinbo},
  title = {Prognostic Stratification of Adjuvant Immunotherapy After Neoadjuvant Chemoimmunotherapy and Quality Surgery in LA-ESCC},
  journal = {The Journal of Thoracic and Cardiovascular Surgery},
  year = {2026},
  doi = {10.1016/j.jtcvs.2026.10.010}
}
Kostenlos starten →